Ligand Pharmaceuticals LGND Proceeds From Derivative Instrument Investing Activities
Proceeds From Derivative Instrument Investing Activities at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromDerivativeInstrumentInvestingActivities.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's proceeds from derivative instrument investing activities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's proceeds from derivative instrument investing activities?
- Ligand Pharmaceuticals (LGND) reported proceeds from derivative instrument investing activities of $431K in Q1 2026.
- What does proceeds from derivative instrument investing activities mean?
- Cash inflows resulting from the sale, maturity, or favorable settlement of derivative instruments held as investments. These proceeds reflect the realized gains or return of capital from financial hedging or speculative activities. Consistent inflows may indicate effective management of the company's derivative portfolio.